Patrys - Crunchbase Company Profile & Funding

Q: Where is Patrys's headquarters?

Patrys is located in Melbourne, Victoria, Australia.

Overview

Patrys

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Patrys

CB Rank

2493669

Patrys is a clinical-stage biotechnology company focused on therapies for human cancers.

Founded

obfuscation

Public

Melbourne, Victoria, Australia

11-50

www.patrys.com

Biotechnology

Health Care

Medical

Therapeutics

Key People

Leodevico Ilag: COO
James Campbel: CEO

Details

Operating Status

Active

Stock Symbol

ASX:PAB

Company Type

For Profit

About the Company

Patrys Limited develops natural human antibody-based therapeutic products for the treatment of lung, pancreatic, gastric, and colon cancers. The company's lead products include PAT-SM6 and PAT-LM1, which are anti-cancer natural human antibodies for the treatment of multiple cancers; and PAT-SC1 that completed Phase I/IIa trial for the

treatment of gastric cancer. It also develops various human antibody discovery programs in infectious diseases for which treatments are needed, including programs in Hepatitis C, malaria, and Staphylococcus A. In addition, the company is exploring opportunities to use its technologies in other disease areas, such as cardiovascular, autoimmune, and central nervous system disorders. Patrys Limited has collaborations with AstraZeneca/Cambridge Antibody Technology and Debiopharm S.A. It operates in Australia, Germany, and the United States. The company was founded in 2006 and is headquartered in Melbourne, Australia.

Phone Number

61 3 9670 3273

Predictions & Insights

Products & Services

PAT-DX1

A deoxymab antibody designed to cross the blood-brain barrier and disrupt DNA damage repair in cancer cells, improving survival in brain and pancreatic cancer models.

PAT-DX3

A full-sized IgG deoxymab antibody that crosses the blood-brain barrier and can deliver therapeutic payloads into brain tissue, including potential use in antibody drug conjugates.